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1. Introduction 
Various methods of cryopreservation of blood, especially erythrocytes, are generally known 
and have been used for a long time. Storage of blood in the frozen state presented one of the 
alternative ways of storing blood components; this possibility was intensively explored in 
the 1950’s and 60’s, when the shelf life of non-frozen red blood cells did not exceed 21 days 
at those times. This time limitation significantly reduced flexibility of usage of RBC products 
and contributed to their dramatically high and wasteful expiration reaching up to 30%. The 
short shelf life of the RBCs resulted in the transfusion services not being able to meet 
demands of quickly evolving surgical disciplines, particularly cardiovascular surgery and 
radical surgical oncology. In military and emergency healthcare, utilization of these three-
week products as a way of creating blood supplies was even more complicated, almost 
unthinkable. The storage of frozen red blood cells therefore presented a great prospect. 
Following the implementation of modern resuspension solutions with addition of 
polysaccharides, phosphates and adenine into everyday practice in the 1970’s and 80’s, the 
general emphasis on the long-term storage of erythrocytes was withdrawn into background. 
In many fields, the now-normal 42-day-long life virtually eliminated the need to perform 
further research since no more than 5 percent of the stored RBC products had to be 
destroyed due to expiration.  
Nevertheless, some areas with a need for long-term storage of red blood cells still remained 
– example being the military transfusion, emergency transfusion service, storage of rare 
blood cells or special autostransfusion programs. In these cases, substantially higher costs of 
the red blood cells production are accepted (when compared to the common storage in 
liquid state). Blood substitution and blood supply is a permanent strategic and logistic 
problem of the military medical services across the world arising from the blood, which is a 
biological drug, has a limited shelf life and needs the special transport and conditions of use. 
The same problem must solve the national health-care authorities in programs of the 
national blood crisis policy, where to get a huge amount of blood supply any time at any 
place in the case of disaster, terrorist attack and war. The therapeutic problems in 
immunohematolgy cases can solve by stock of rare blood, storage of autologous blood for 
patients with rare erythrocyte antigens and storage of autologous blood for patients with 
red blood cell alloantibodies with no chance to use common blood. All mentioned demands 
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highly correspond with stock of frozen blood. New global security risks exalt this problem 
to all-society relevancy. 
2. Methods of cryopreservation of living tissues and cells 
Throughout the years, tackling the matter of cryopreservation of cells and tissues has been 
deriving from findings about the protection of cells against the impacts of frost, especially 
from the knowledge about production of ice crystals that cause the subsequent destruction 
of cellular structures and membranes [1916]. As early as 1866, French naturalist Félix-
Archimède Pouchet first described that frozen erythrocytes are destroyed after thawing [16]. 
This effect had long been attributed solely to the mechanical damage that cells suffer from 
ice crystals generated in the course of freezing.  
As we know now thanks to physical chemistry, however, during the changing process of 
aqueous solutions into solid state, it is water that changes its state of matter first. Water 
crystals are created from pure water, while the space in between them is filled with 
concentrated electrolyte. This leads to cellular dehydration and to the pH change. Based on 
this knowledge, James Lovelock came up with a hypothesis in 1953, suggesting that the 
damage effects of frost to cells first induce the cells dehydration and pH changes. Those 
mechanisms destroy cell membrane before mechanical injury caused by ice crystals. This 
evolved into a generally accepted theory [6,10,11,19].  
Protection of cells from freezing is achieved by adding so-called cryoprotective substances. 
Since these cryoprotectants usually cause a significant increase in osmolality, it is 
nevertheless necessary to have all the procedures monitored, and to have osmotic changes 
under control, in order to avoid an irreversible damage to cellular structures and 
membranes caused by them [6,11,17] . 
With regard to the types of their effects, cryoprotectants are divided into two groups: 
2.1 Intracellular (penetrative) cryoprotectants 
Due to their relatively simple chemical structure, these substances penetrate the cellular 
membrane and do not present any toxic danger for the cell when in low concentration. 
Glycerol, dimethyl sulfoxide (DMSO) and certain types of glycol (ethanol, propylenglycol, 
methanol, etc.) belong among them. In terms of utilization, they are mostly applied when 
the long-term preservation of frozen tissues is needed (e.g., sperm banks, erythrocyte 
cryobanks, banks for stem cells and umbilical cells).  
There has not been fully clarified the mechanism of the effect of penetrative cryoprotectants 
yet. Initially, the damage of cells was associated with the effect of ice crystals only. 
Cryoprotective substances, nevertheless, besides limiting the creation or frozen crystals, also 
modify these crystals’ shape and size, and by changing their ionic ratio intracellularly as 
well as extracellularly, they also eliminate the damage caused by osmotic shock which 
otherwise occurs during freezing. During the freezing process, penetrative cryoprotectants 
increase output of intracellular water, maintaining the osmotic balance in a partially frozen 
extracellular solution in this way. It results in not only reducing the cells’ volume but also in 
the reduction of the osmotic load. With regard to subsequent survival of cells after their 
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thawing, a significant effect is the inhibition of APT caused by some of the cryoprotectants 
such as glycerol and DMSO [15,23]. 
Glycerol: Cryoprotective effect of glycerol, that is also called low-molecular nonelectrolyte, 
was first described on sperms. Its cryoprotective effect lies in penetrating the cellular 
membrane into the cell’s nucleus and creating a hyperosmotic environment. It used to be 
utilized for cryopreservation of large numbers of mammals’ cells, as well as for embryos 
and unfertilized eggs. Now it is mostly used for erythrocyte cryopreservation. Glycerol is 
mostly used in concentration of 1.0 - 2.0 M, 20 - 40% (55% max.) respectively. 
Dimethyl sulfoxide (DMSO): Just like glycerol, DMSO is a nonelectrolyte with low 
molecular mass. With regard to its cryoprotective quality, it has a similar effect to glycerol. 
As opposed to glycerol, however, it is more likely to become toxic - already at a 
concentration of 1.0 M. 
Propylene glycol (PROH): Its cryprotective effects are caused by its entirely amorphous 
state that it reaches in an aqueous solution. PROH excels in stability in temperatures below 
the freezing point. Thereby it limits crystallization during the freezing and de-freezing 
process. PROH is usually used in combination with other substances, aiming to limit the 
possibility of a specific toxic and osmotic damage to tissues and cells. 
2.2 Extracellular (non-penetrative) cryoprotectants 
Due to their molecular mass, these substances do not penetrate cellular membrane and are 
mostly used for rapid and ultra-rapid freezing. There are many possible examples, of which 
several should be named: monosaccharides (glucose, hexose), disaccharides (sucrose, 
trehalose), trisaccharides (raffinose) and polymers (polyvinylpyrrolidone, polyethylene 
glycol) and other macromolecular substances such as dextran, modified gelatin, 
hydroxyethyl starch or albumin. 
The mechanism of the non-penetrative cryoprotectants effect lies in their ability to stabilize 
cellular membrane and also in so called vitrification. When there is water (with temperature 
below 0°C) turning into ice, non-penetrative cryoprotectants remain outside the cells, where 
they secure the creation interspaces between cellular membrane and extracellular 
environment. Electrolytes segregated from freezing solutions are being concentrated in 
these interspaces. As a consequence to change in osmotic ratio, extracellular hypertonicity 
removes water from a slowly freezing intracellular space. Moreover, the subsequent 
decrease in the osmotic differences does not damage the cell membrane. One needs to be 
cautious with the increase in hypertonicity of cooled cells as it may results in osmotic shock 
if the thawing process takes too long [5,18] . 
3. Cryopreservation of red cells 
Only recently the great limiting factor of cryopreservation of red blood cells has been at least 
partially solved - the life of erythrocytes after thawing was merely one day, which 
drastically limited the operational use of the given product. With the discovery of new 
technologies and resuspension solutions in the past years, the life of the blood after its 
thawing (“reconstitution”) was extended to 1 - 3 weeks. 
www.intechopen.com
 
Blood Transfusion in Clinical Practice 
 
236 
The current practice takes advantage of the erythrocytes cryopreservation and the 
intracellular cryoprotectant glycerol is used almost exclusively. Its cryoprotective effects has 
been known since 1949 when the sperm cells were frozen. Only a year later, in 1950, glycerol 
was firstly used for the freezing of erythrocytes. Thawed RBCs were first successfully 
transfused in 1951 by Mollison [13]. The method used low, 20% concentration of glycerol 
and quick freezing, discovered by A.U.Smith [17].  
The routine clinical use of cryopreservation of erythrocytes was first implemented in the 
United States in early 1960’s. Since the beginning, a method of cryopreservation was used 
freezing erythrocytes in high glycerol, i.e. with the addition of 40% glycerol to erythrocytic 
suspension. This method is now common in most departments dealing with RBC. The 
freezing process is slow, and it takes place at -80 °C in mechanical freezers. The frozen red 
cells are then stored in -65 °C. The method was first described by J.L.Tullis in 1958 [21,22]. 
Notwithstanding, the main reason for introducing this method was pragmatic - standard 
PVC bags were not applicable for this method and there were problems with obtaining 
license that would give way to the production of aluminum containers for the storage of 
RBC in liquid nitrogen. In other words, it was not the question of the quality of the 
erythrocytes that were frozen using this method. The complication of this method was 
caused by storage issues. Although special plastic bags for cryopreservation at -200 °C did 
appear on the market in the next 10 years, the already suffered massive investments into 
mechanical freezers, as well as high cost of liquid nitrogen in the U.S., meant that the 
method of freezing in high glycerol became the North American standard. 
An alternative method of freezing and storing red blood cells in glycerol is rapid freezing in 
liquid nitrogen at -196 °C (40 °C / min) and subsequent storing in nitrogen vapors at -170°C. 
The method was first described by Pert et al. in 1963 [15]. In addition to lower 
concentrations of glycerol (5-20%) which is easier to wash off, the advantage of this method 
lies in its independence on the sources of electrical energy, thus reducing the risk of 
endangering the stored product. There are significant practical week points of this method: 
they are handling of liquid nitrogen containers, transport issues and also the scheme of 
Deward containers. This method had become widely used in Europe for some time, where 
cryopreservative procedures were being implemented into practice 10 years later than in the 
US, i.e. in early 1970’s. At that time, plastic bags suitable for use in extremely cold 
temperatures were already available, liquid nitrogen was more affordable in Europe and, 
unlike in the US, mechanical deep-freeze boxes represented a very high investment. 
There was another reason why the way of European practice headed towards this method. It 
was the simplicity of the deglycerolization process which can be, at low concentration, 
accomplished by manual methods, or by using special rinsing attachments in a centrifuge, such 
as the ADL cell-washing bowl (in contrast with rinsing of highly concentrated glycerol which 
requires more complex technique and more sophisticated technical equipment). The 
comparison of RBCs cryopreservation in high glycerol and low glycerol is displayed in Table 1. 
Turning to the non-penetrative cryoprotectants, there is particularly the hydroxyethyl starch 
(HES) in the spotlight. Its usage in the field of erythrocytes cryopreservation was patented in 
the U.S. in 1991. Its benefits are the bio-compatible properties of macromolecular 
polysaccharides (including HES, which is commonly used as volume expander) at higher 
concentrations, that do not require any complex rinsing procedure during the process of 
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thawing and reconstitution, and so the defrosted product may be directly transfused. 
Disadvantage of HES is the freezing and storage in liquid nitrogen and relative higher 
haemolysis after thawing. 
 
 glycerol 40% glycerol 20% 
Freezing temperature -80°C -197°C 
Freezing rate slow fast 
Freezing technique mechanically freezer liquid Nitrogen 
Storage temperature min. -65°C min.-120°C 
Impact of temperature 
changes 
thawing and refreezing is 
possible 
critical 
Containers PVC, polyolefin polyolefin 
Transportation dry ice Nitrogen vapor 
Time of deglycerolization 60 min. 30 min. 
Hematocrit 55-70% 50-70% 
Leucodepletion 94-99% 95% 
Table 1. The comparison of RBCs cryopreservation in 40% glycerol and 20% glycerol 
Despite the fact that deep-frozen tissues and cells (i.e. erythrocytes) can be preserved almost 
indefinitely (on condition they are provided with an appropriate storage temperature), it 
was necessary to determine an administratively acceptable storage time. Only in 1987 the 
United States Food and Drug Administration (FDA) set the life of at -80°C frozen RBCs to be 
10 years. This time limit was adopted by other countries as well. In 2010, European 
legislation prolonged the frozen erythrocytes’ administrative life up to 30 years, depending 
on the storage method (Directive 2044/33/EC). According to the Guide to the Preparation, use 
and quality assurance of blood components (No.R Recommendation (95) 15 Council of Europe), 
“the storage of frozen RBCs may be extended to at least ten years if the correct storage 
temperature can be guaranteed.” [7,26,27]. 
From the practical point of view, the usability of erythrocytes after reconstitution, i.e. after 
defrosting and deglycerolization, is a more important parameter than their storage time in a 
frozen state. For a long time, reconstituted erythrocytes expired after 24 hours, which 
greatly limited their flexibility and possibilities of their usage. This did not change even after 
the introduction of semi-automated deglycerolization systems in 1970’s (Haemonetics ACP-
115, IBM Cell Washer, Elutramatic cell washer). There came a revolutionary breakthrough 
and significant prolongation of the erythrocytes life after thawing after the fully automated 
device (Haemonetics ACP-215) had been invented and homologated for general usage by 
FDA in 2011. This invention made the glycerolization as well as the deglycerolization 
possible in a fully closed manner, while locking it out of external environment and thus 
performing it out of contact with this external environment. 
C. Robert Valery and his team from the Naval Research Blood Laboratory in particular proved 
the applicability of cryopreserved red blood cells 7 days after reconstitution when using 
conventional resuspension solutions (SAG-M), and 14 days after reconstitution when using 
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AS-3 solution (Nutricel) [4,24,25]. Subsequently, Bohonek et al. proved the applicability of 
cryopreserved erythrocytes 3 weeks after reconstitution, also when using AS-3 [1]. 
 
Fig. 1. The line of deglycerolization (washing) machines Haemonetics ACP-115 – first fully 
automated machines 
 









Fig. 3. Mechanical freezers for deep freezing (-65°C - -80°C) 
 
Fig. 4. Stock of frozen blood. 
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Fig. 5. Frozen RBCs units 
4. Cryopreservation of platelets 
Platelet could be cryopreserved in different cryoprotectives: intracellular (DMSO, glycerol) 
as well as in extracellular (HES, dextran).  
The most widely used method for the platelets cryopreservation is freezing in 5-10% DMSO 
at -80 °C with their storage at -65 °C. This method is easy and does not need any technical 
equipment. After thawing, the platelets are suspended in thawed plasma and there is no 
need to wash out the cryoprotectant.  
Although the platelets stored by cryopreservation are efficient in hemostasis, they are 
affected by a number of functional defects during storage and preparation for transfusion. 
Approximately 15% of cryopreserved platelets lost surface-bound GPIb, while there was no 
measurable loss of GPIIB/IIIa during cryopreservation. The cryopreserved platelets also 
showed a significant decrease in aggregation to ristocetin, but no loss of response to the 
stronger agonist, thrombin. Even though these defects are of a minor clinical relevance and 
the cryopreserved platelets were shown to be safe and effective for treatment of abnormal 
bleeding, it is still necessary to reckon with these changes [2,3,14,20]. 
5. Conclusion 
The cryopreservation of blood is a method which solves various problems in blood 
transfusion service.  The main application is in military medicine and blood crisis policy, but 
also in special transfusiology fields, such as the storage of rare red blood cells and long-term 
storage of autologous blood. Thanks to modern procedures, which allow for prolonged shelf 
time after thawing and reconstitution of frozen blood, the use of frozen blood is now more 
flexible and less limited.  
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